These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Hand-foot syndrome after administration of tyrosinkinase inhibitors].
    Author: Bednaríková D, Kocák I.
    Journal: Klin Onkol; 2010; 23(5):300-5. PubMed ID: 21061680.
    Abstract:
    At present, the dermal toxicity of anti-cancer drugs is ever more apparent in cancer patients. This phenomenon appears, in particular, in relation to the increased administration of targeted anti-cancer treatment, especially of monoclonal antibodies and tyrosinkinase inhibitors (TKI), towards various receptors of growth factors which are applied in the ethiopathogenesis of a tumour cell. Our article focuses on the palmoplantar erythrodysesthesia syndrome, designated also as the hand-foot skin reaction (HFSR), which most frequently occurs in patients treated with TKI sorafenib and sunitinib. Developed HFSR may be a strongly perceived adverse effect for patients and may lead to dose intensity reduction in the targeted treatment, or to its interruption if necessary. However, a correct approach from the oncologist and dermatologist, including instructions to be provided to the patient on how to prevent a serious grade of HFSR from being developed, may ensure a smooth anti-cancer treatment and a satisfactory quality of life for cancer patients.
    [Abstract] [Full Text] [Related] [New Search]